Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18472808 | 0.89 | PTGER2 (0.41) | TYMSTHRATHRB | |
| SCHEMBL21663328 | 0.86 | TYMS (0.40) | TYMSPTGS2AKR1C3AKR1C2CYP1A2 | |
| SCHEMBL9607893 | 0.83 | TYMS (0.36) | TYMSPTGS2THRATHRB | |
| SCHEMBL9607786 | 0.83 | THRB (0.42) | TYMSCYP2C19THRATHRB | |
| SCHEMBL9607890 | 0.82 | TYMS (0.42) | TYMSMAPTTHRATHRB | |
| SCHEMBL2604628 | 0.82 | AKR1C3 (0.46) | PTGS2AKR1C3AKR1C2FAAH | |
| SCHEMBL15338864 | 0.81 | TYMS (0.38) | TYMSMAPTTHRATHRB | |
| SCHEMBL20664389 | 0.81 | PTGS2 (0.35) | TYMSPTGS2AKR1C3AKR1C2THRA | |
| SCHEMBL2604627 | 0.81 | CYP1A2 (0.44) | TYMSCYP1A2MAPTCYP2C19 | |
| SCHEMBL9607781 | 0.81 | THRB (0.37) | TYMSAKR1C3AKR1C2MAPTTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394468-B2 | Polymerizable compound and liquid crystal composition including it | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8394468-B2 | Polymerizable compound and liquid crystal composition including it | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | KLK3, PDE7A, FZD7 | TYMS 1755/4885PTGS2 2451/4885AKR1C3 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.